Exhibit 4.1

 


 



FIFTH SUPPLEMENTAL INDENTURE

 

ST. JUDE MEDICAL, INC.

 

AND

 

U.S. BANK NATIONAL ASSOCIATION,
 AS TRUSTEE

 

Fifth Supplemental Indenture

 

Dated as of September 23, 2015

 

Supplementing the Indenture

 

Dated as of July 28, 2009


 



 











 

FIFTH SUPPLEMENTAL INDENTURE, dated as of September 23, 2015 (this “Fifth Supplemental Indenture”), between St. Jude Medical, Inc., a corporation duly organized and existing under the laws of Minnesota (herein called the “Company”), and U.S. Bank National Association, as Trustee (herein called “Trustee”);

 

RECITALS:

 

WHEREAS, the Company and the Trustee have heretofore executed and delivered an Indenture, dated as of July 28, 2009 (the “Base Indenture” and, together with the Fifth Supplemental Indenture, the “Indenture”), providing for the issuance from time to time of the Company’s debentures, notes or other evidences of indebtedness (herein and therein called the “Securities”), to be issued in one or more series as provided in the Base Indenture;

 

WHEREAS, Section 12.1 of the Base Indenture permits the Company and the Trustee to enter into an indenture supplemental to the Base Indenture to establish the form and terms of any series of Securities;

 

WHEREAS, Section 2.1 of the Base Indenture permits the form of Securities of any series to be established in an indenture supplemental to the Base Indenture;

 

WHEREAS, Section 3.1 of the Base Indenture permits certain terms of any series of Securities to be established pursuant to an indenture supplemental to the Base Indenture;

 

WHEREAS, pursuant to Sections 2.1 and 3.1 of the Base Indenture, the Company desires to provide for the establishment of three new series of Securities under the Base Indenture, the form and substance of such Securities and the terms, provisions and conditions thereof to be set forth as provided in the Base Indenture and this Fifth Supplemental Indenture; and

 

WHEREAS, all things necessary to make this Fifth Supplemental Indenture a valid agreement of the Company, in accordance with its terms, have been done.

 

NOW, THEREFORE, for and in consideration of the foregoing and the purchase of the Securities of the three new series established by this Fifth Supplemental Indenture by the holders thereof (the “Holders”), it is mutually agreed, for the equal and proportionate benefit of all such Holders, as follows:

 

ARTICLE 1

 

DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION

 

Section 1.01 Relation to Base Indenture.  This Fifth Supplemental Indenture constitutes a part of the Base Indenture (the provisions of which, as modified by this Fifth Supplemental Indenture, shall apply to the Notes (as defined in Section 2.01)) in respect of the Notes but shall not modify, amend or otherwise affect the Base Indenture insofar as it relates to any other series of Securities or modify, amend or otherwise affect in any manner the terms and conditions of the Securities of any other series.

 

1











 

Section 1.02 Definitions.  For all purposes of this Fifth Supplemental Indenture, the capitalized terms used herein (i) which are defined in this Section 1.02 have the respective meanings assigned hereto in this Section 1.02 and (ii) which are defined in the Base Indenture (and which are not defined in this Section 1.02) have the respective meanings assigned thereto in the Base Indenture.  For all purposes of this Fifth Supplemental Indenture:

 

(a)        Unless the context otherwise requires, any reference to an Article or Section refers to an Article or Section, as the case may be, of this Fifth Supplemental Indenture;

 

(b)        The words “herein,” “hereof” and “hereunder” and words of similar import refer to this Fifth Supplemental Indenture as a whole and not to any particular Article, Section or other subdivision;

 

(c)        Headings are for convenience of reference only and do not affect interpretations; and

 

(d)       The terms defined in this Section 1.02(d) have the meanings assigned to them in this Section and include the plural as well as the singular:

 

“2018 Notes” has the meaning set forth in Section 2.01(a).

 

“2020 Notes” has the meaning set forth in Section 2.01(a).

 

“2025 Notes” has the meaning set forth in Section 2.01(a).

 

“Agreement and Plan of Merger” means the Agreement and Plan of Merger, dated July 21, 2015 between the Company, SJM International, Inc., Spyder Merger Corporation and Thoratec Corporation.

 

“Interest Payment Date” has the meaning set forth in Section 2.01(d).

 

“Interest Period” has the meaning set forth in Section 2.01(d).

 

“Maturity Date” has the meaning set forth in Section 2.01(c).

 

“Notes” has the meaning set forth in Section 2.01(a).

 

“Special Mandatory Redemption Date” means the earlier to occur of (1) March 22, 2016, if the Closing (as defined in the Agreement and Plan of Merger) has not occurred on or prior to January 21, 2016, or (2) the 60th day (or if such day is not a Business Day, the first Business Day thereafter) following the termination of the Agreement and Plan of Merger for any reason.

 

2











 

ARTICLE 2

 

GENERAL TERMS AND CONDITIONS OF THE NOTES

 

Section 2.01 Terms of Notes.  Pursuant to Sections 2.1 and 3.1 of the Base Indenture, there are hereby established three new series of Securities, the terms of which shall be as follows:

 

(a)        Designation.  There are hereby authorized and established three new series of Securities under the Base Indenture, known and designated as the “2.000% Senior Notes due 2018” (the “2018 Notes”), the “2.800% Senior Notes due 2020” (the “2020 Notes”) and the “3.875% Senior Notes due 2025” (the “2025 Notes” and, together with the 2018 Notes and 2020 Notes, the “Notes”) of the Company.  Each series of Notes is unlimited in aggregate principal amount.  The initial aggregate principal amount of the 2018 Notes to be issued under this Fifth Supplemental Indenture shall be $500,000,000, the initial aggregate principal amount of the 2020 Notes to be issued under this Fifth Supplemental Indenture shall be $500,000,000 and the initial aggregate principal amount of the 2025 Notes to be issued under this Fifth Supplemental Indenture shall be $500,000,000.  Any additional amounts of the Notes to be issued shall be set forth in a Company Order.

 

(b)        Form and Denominations.  The Notes will be issued only in fully registered form, and the authorized denominations of the Notes shall be $2,000 principal amount and any integral multiple of $1,000 in excess thereof.  The Notes will initially be issued in the form of one or more Global Securities substantially in the form of Exhibit A attached hereto, with such modifications thereto as may be approved by the authorized officer executing the same.  The Notes will be denominated in U.S. dollars and payments of principal, premium, if any, and interest will be made in U.S. dollars.

 

(c)        Maturity Date.  The Stated Maturity of principal for the 2018 Notes shall be September 15, 2018, the Stated Maturity of principal for the 2020 Notes shall be September 15, 2020 and the Stated Maturity of principal for the 2025 Notes shall be September 15, 2025 (each, the “Maturity Date”).

 

(d)       Interest.  Interest on the Notes payable on any Interest Payment Date (as defined below), the respective Maturity Date, or if applicable, the Redemption Date (as determined in accordance with Section 4.2 of the Base Indenture) shall be the amount accrued from, and including, the immediately preceding Interest Payment Date in respect of which interest has been paid or duly provided for (or from, and including, the original issue date of September 23, 2015, if no interest has been paid or duly provided for with respect to the Notes) to, but excluding, such Interest Payment Date, Maturity Date or, if applicable, Redemption Date, as the case may be (each, an “Interest Period”).  The Notes will bear interest at the rate of 2.000% per year for the 2018 Notes, 2.800% for the 2020 Notes and 3.875% per year for the 2025 Notes from the original issue date thereof to the respective Maturity Date.  Interest on the Notes shall be payable semi-annually in arrears on March 15 and September 15 of each year, beginning on March 15, 2016 (each such date, an “Interest Payment Date”).  The amount of interest payable for any semi-annual Interest Period will be computed on the basis of a 360-day year consisting of twelve 30-day months.  In the event any Interest Payment Date on or before

 

3











 

the Maturity Date falls on a day that is not a Business Day, the interest payment due on that date will be postponed to the next day that is a Business Day and no interest shall accrue as a result of such postponement.

 

In the event the Maturity Date or a Redemption Date for any Note falls on a day that is not a Business Day, then the related payments of principal, premium, if any, and interest may be made on the next succeeding date that is a Business Day (and no additional interest will accumulate on the amount payable for the period from and after the Maturity Date for such Note).  The term “Business Day” means, with respect to any Note, any day, other than a Saturday, Sunday or any other day on which banking institutions in the City of New York are authorized or obligated by law or executive order to close.  Interest due on the Maturity Date or a Redemption Date (in each case, whether or not an Interest Payment Date) will be paid to the Person to whom principal of such Notes is payable.

 

(e)        Sinking Fund; Holder Repurchase Right.  The Notes shall not be subject to any sinking fund or analogous provision or be redeemable at the option of the Holders.

 

(f)        Forms.  The Notes shall be substantially in the form of Exhibit A attached hereto, with such modifications thereto as may be approved by the authorized officer executing the same.

 

(g)        Appointment of Agent.  The Trustee will initially be the Registrar and Paying Agent with respect to the Notes.

 

(h)        Satisfaction and Discharge of Indenture/Defeasance.  Until the applicable Maturity Date, the Notes will be subject to Sections 11.2 and 11.3 of the Base Indenture; provided, however, that in connection with any deposit of funds with the Trustee pursuant to Section 11.2 of the Base Indenture upon any redemption that requires the payment of a premium, the amount deposited with the Trustee will be sufficient to the extent that an amount is deposited with the Trustee equal to the premium calculated as of the date of the notice of redemption, with any deficit on the Redemption Date required to be deposited with the Trustee on or prior to the Redemption Date.

 

(i)         Further Issues.  The Company may from time to time, without the consent of the Holders of either series of Notes, issue additional Notes with respect to either such series.  Any such additional Notes will have the same ranking, interest rate, maturity date and other terms as the respective series of Notes.  Any such additional Notes, together with the related series of Notes herein provided for, will constitute a single series of Securities under the Indenture; provided that if such additional Notes are not fungible with the related series of Notes provided for herein for United States federal income tax purposes, such additional Notes shall have one or more separate CUSIP numbers.

 

ARTICLE 3

 

EVENTS OF DEFAULT

 

Section 3.01 Events of Default.  Pursuant to Section 3.1 of the Base Indenture, the term “Event of Default” with respect to each series of Notes shall include, in addition to those

 

4











 

otherwise set forth in Section 7.1 of the Base Indenture, the following: the occurrence with respect to any Debt of the Company in an aggregate principal amount of $75,000,000 or more of (a) an event of default that results in such Debt becoming due and payable prior to its scheduled maturity (after giving effect to any applicable grace period) or (b) the failure to make any payment when due (including any applicable grace period) which results in the acceleration of the maturity of such Debt, in each case without such acceleration having been rescinded, annulled or otherwise cured.

 

ARTICLE 4

 

REDEMPTION OF THE NOTES

 

Section 4.01 Optional Redemption by Company.  Each series of Notes may be redeemed at the option of the Company on the terms and conditions set forth in the form of Note as set forth as Exhibit A.

 

Section 4.02 Special Mandatory Redemption. In the event that the Closing has not occurred on or prior to the earlier of January 21, 2016 and the date the Agreement and Plan of Merger is terminated, the Company shall redeem the 2018 Notes and the 2025 Notes on the terms and conditions set forth in the form of Note as set forth as Exhibit A.

 

ARTICLE 5

 

CHANGE OF CONTROL

 

Section 5.01 Offer to Purchase Upon Change of Control Triggering Event.  Upon the occurrence of a Change of Control Triggering Event (as defined in the form of Note set forth as Exhibit A), and unless the Company has exercised its option to redeem the Notes pursuant to Section 4.01, the Company shall be required to make an offer to each Holder of the applicable series of the Notes to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of that Holder’s Notes on the terms and conditions set forth in the form of Note set forth as Exhibit A.

 

ARTICLE 6

 

MISCELLANEOUS

 

Section 6.01 Relationship to Existing Base Indenture.  This Fifth Supplemental Indenture is a supplemental indenture within the meaning of the Base Indenture.  The Base Indenture, as supplemented and amended by this Fifth Supplemental Indenture, is in all respects ratified, confirmed and approved and, with respect to the Notes, the Base Indenture, as supplemented and amended by this Fifth Supplemental Indenture, shall be read, taken and construed as one and the same instrument.

 

Section 6.02 Modification of The Existing Base Indenture.  Except as expressly modified by this Fifth Supplemental Indenture, the provisions of the Base Indenture shall govern the terms and conditions of the Notes.

 

5











 

Section 6.03 Governing Law.  This Fifth Supplemental Indenture shall be governed by and construed in accordance with the laws of the State of New York.

 

Section 6.04 Counterparts.  This Fifth Supplemental Indenture may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument.

 

Section 6.05 Trustee Makes No Representation.  The recitals contained herein are made by the Company and not by the Trustee, and the Trustee assumes no responsibility for the correctness thereof.  The Trustee makes no representation as to the validity or sufficiency of this Fifth Supplemental Indenture (except for its execution thereof and its certificates of authentication of the Notes).

 

Section 6.06 Separability.  In case any provision in the Base Indenture, this Fifth Supplemental Indenture or the Notes shall for any reason be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

 

[Signature page follows]

 

6











 

IN WITNESS WHEREOF, the parties hereto have caused this Fifth Supplemental Indenture to be duly executed and attested all as of the day and year first above written.

 

Dated: September 23, 2015

 

	
 
    	
 
    	
     ST. JUDE MEDICAL, INC.,
    
	
 
    	
 
    	
     as   Issuer
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
  /s/   Donald J. Zurbay
    
	
 
    	
 
    	
  Name:
    	
Donald J.   Zurbay
    
	
 
    	
 
    	
  Title:
    	
Vice   President, Finance and
    
	
 
    	
 
    	
 
    	
Chief   Financial Officer
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
     U.S. BANK NATIONAL   ASSOCIATION,
    
	
 
    	
 
    	
     as Trustee
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
By:
    	
  /s/   Raymond S. Haverstock
    
	
 
    	
 
    	
  Name:
    	
Raymond   S. Haverstock
    
	
 
    	
 
    	
  Title:
    	
Vice President
    


 

[Signature Page to Fifth Supplemental Indenture]

 











 

EXHIBIT A
 Form of Senior Notes

 

THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE OF THE DEPOSITARY WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE OR ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS SECURITY FOR ALL PURPOSES.  THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE.

 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

 

ST. JUDE MEDICAL, INC.

 

	
No.       
    	
CUSIP NO./ISIN NO. [2018 Notes: 790849 AL7 /   US790849AL71]
    
	
 
    	
[2020   Notes: 790849 AM5 / US790849AM54]

[2025   Notes: 790849 AN3 / US790849AN38]
    
	
 
    	
$                        
    


 

 

Interest.  St. Jude Medical, Inc., a corporation duly incorporated and subsisting under the laws of the State of Minnesota (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co., or registered assigns, the principal sum of                           DOLLARS ($           ), as revised by the Schedule of Increases or Decreases in Global Security attached hereto, on [2018 Notes: September 15, 2018] [2020 Notes: September 15, 2020] [2025 Notes: September 15, 2025] and to pay interest thereon from September 23, 2015 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, semi-annually on March 15 and September 15 in each year, commencing March 15, 2016, at the rate of [2018 Notes: 2.000%] [2020 Notes: 2.800%] [2025 Notes: 3.875%] per annum, until the principal hereof is paid or made available for payment.

 

Method of Payment.  The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose

 

A-1











 

name this Security (or one or more Predecessor Securities) is registered at the close of business on the record date for such interest, which shall be the March 1 or September 1 (whether or not a Business Day) (each, a “Regular Record Date”), as the case may be, next preceding such Interest Payment Date.  Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture.

 

Payment of the principal of (and premium, if any) and interest on this Security will be made at the office or agency of the Trustee maintained for that purpose in New York, New York, in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts.

 

Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place.

 

Authentication.  Unless the certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose.

 

A-2











 

IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its corporate seal.

 

Dated: September 23, 2015

 

	
 
    	
ST. JUDE MEDICAL, INC.
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    
	
 
    	
 
    	
Title:
    


 

A-3











 

[FORM OF CERTIFICATION OF AUTHENTICATION]

 

CERTIFICATE OF AUTHENTICATION

 

This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture.

 

	
 
    	
U.S. BANK NATIONAL ASSOCIATION,
    
	
 
    	
as   Trustee
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Authorized   Signatory
    


 

A-4












 

[Form of Reverse of Note]

 

Indenture.  This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to be issued in one or more series under an Indenture, dated as of July 28, 2009 (herein called the “Base Indenture”, which term shall have the meaning assigned to it in such instrument), as supplemented by a Fifth Supplemental Indenture, dated as of September 23, 2015 (herein called the “Fifth Supplemental Indenture”, and together with the Base Indenture, the “Indenture”), between the Company and U.S. Bank National Association, as Trustee (herein called the “Trustee,” which term includes any successor trustee under the Indenture), and reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered.  This Security is one of the series designated on the face hereof, initially limited in aggregate principal amount to $500,000,000.  The Company may at any time issue additional securities under the Indenture in unlimited amounts having the same terms as the Securities; provided that if such additional securities are not fungible with this Security for U.S. federal income tax purposes, such additional securities shall have one or more separate CUSIP numbers.

 

Optional Redemption.  The Securities of this series are subject to redemption at the Company’s option, [2020 and 2025 Notes: (A)] at any time and from time to time, until [2018 Notes: September 15, 2018] [2020 Notes: August 15, 2020 (one month prior to the Maturity Date of the Securities)] [2025 Notes: June 15, 2025 (three months prior to the Maturity Date of the Securities)], in whole or in part, upon not less than 30 nor more than 60 days’ notice delivered to each Holder of Securities to be redeemed at his address as it appears in the records of the Registrar, on any date prior to their Stated Maturity at a Redemption Price equal to the greater of (i) 100% of the principal amount of such Securities to be redeemed, plus accrued and unpaid interest thereon to the Redemption Date and (ii) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the Redemption Date) [2020 and 2025 Notes: that would be due if such Securities matured on the Par Call Date], in each case, as determined by an Independent Investment Banker (as defined below), discounted to the Redemption Date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined below), plus [2018 Notes: 20] [2020 Notes: 20] [2025 Notes: 30] basis points, plus accrued and unpaid interest thereon to, but excluding, the Redemption Date; provided that unless the Company defaults in payment of the Redemption Price, on or after the Redemption Date, interest will cease to accrue on the Securities or portions thereof called for redemption [2020 and 2025 Notes: ; or (B) on or after [2020 Notes: August 15, 2020] [2025 Notes: June 15, 2025] ([2020 Notes: one] [2025 Notes: three] month[s] prior to the Maturity Date of the Securities), in whole at any time or in part from time to time, at a Redemption Price equal to 100% of the aggregate principal amount of the Securities being redeemed, plus accrued and unpaid interest, if any, to, but excluding, the Redemption Date.]

 

For purposes of determining the optional redemption price, the following definitions are applicable:

 

A-5











 

“Treasury Rate” means, with respect to any Redemption Date, the rate per annum equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, calculated on the third business day preceding the Redemption Date, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the related Comparable Treasury Price for such Redemption Date. With respect to any Redemption Date in connection with a satisfaction and discharge or defeasance pursuant to Section 11.2 or 11.3 of the Indenture, respectively, the Treasury Rate will be calculated as of the third Business Day preceding the date that the Company deposits funds to pay the Redemption Price with the Trustee.

 

“Comparable Treasury Issue” means the United States Treasury security or securities selected by the Independent Investment Banker as having a maturity comparable to the remaining term of the Securities to be redeemed [2020 and 2025 Notes: (assuming for this purpose that the Securities matured on the Par Call Date)] that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Securities.

 

“Comparable Treasury Price” means, with respect to any Redemption Date, (1) the average of the Reference Treasury Dealer Quotations for such Redemption Date, after excluding the highest and lowest Reference Treasury Dealer Quotations, or (2) if the Independent Investment Banker obtains fewer than four Reference Treasury Dealer Quotations, the average of all Reference Treasury Dealer Quotations so received.

 

“Independent Investment Banker” means the Reference Treasury Dealer appointed by the Company.

 

[2020 and 2025 Notes: “Par Call Date” means [2020 Notes: August 15, 2020 (one month prior to the Maturity Date of the Securities)] [2025 Notes: June 15, 2025 (three months prior to the Maturity Date of the Securities)].]

 

“Reference Treasury Dealer” means Merrill Lynch, Pierce, Fenner & Smith Incorporated and a Primary Treasury Dealer (as defined herein) selected by Wells Fargo Securities, LLC, and its successors and one other nationally recognized investment banking firm; provided, however, that, if the foregoing shall cease to be a primary U.S. Government securities dealer in New York City (a “Primary Treasury Dealer”), the Company shall substitute therefor another nationally recognized investment banking firm that is a Primary Treasury Dealer.

 

“Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any Redemption Date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue for the Securities (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day preceding such Redemption Date.

 

[2018 and 2025 Notes: Special Mandatory Redemption. In the event that the Closing (as defined in the Agreement and Plan of Merger) has not occurred on or prior to the earlier of January 21, 2016 and the date the Agreement and Plan of Merger is terminated, the Company will be

 

A-6











 

required to redeem all outstanding Securities on the Special Mandatory Redemption Date at a redemption price equal to 101% of the aggregate principal amount thereof, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date (the “Special Mandatory Redemption Price”). Notwithstanding the foregoing, installments of interest on the Securities that are due and payable on Interest Payment Dates falling on or prior to the Special Mandatory Redemption Date will be payable on such Interest Payment Dates to each Holder of Securities as of the close of business on the relevant Regular Record Dates in accordance with the Securities and the Indenture.  The Company will cause the notice of special mandatory redemption to be delivered electronically or mailed, with a copy to the Trustee, within ten Business Days after the occurrence of the event triggering the special mandatory redemption to each Holder of Securities at his address as it appears in the records of the Registrar. If funds sufficient to pay the Special Mandatory Redemption Price of the Securities to be redeemed on the Special Mandatory Redemption Date are deposited with the Trustee or a Paying Agent on or before such Special Mandatory Redemption Date, and certain other conditions are satisfied, on and after such Special Mandatory Redemption Date, the Securities will cease to bear interest.]

 

In the event of redemption of this Security in part only, a new Security or Securities of this series and of like tenor for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof.

 

Change of Control.  If a Change of Control Triggering Event occurs, unless the Company has exercised its right to redeem the Securities as described above, it will be required to make an offer to repurchase all, or any part (equal to $2,000 or any integral multiples of $1,000 in excess thereof), of each Holder’s Securities pursuant to the offer described below (the “Change of Control Offer”) on the terms set forth herein.  In the Change of Control Offer, the Company will be required to offer payment in cash equal to 101% of the aggregate principal amount of Securities repurchased plus accrued and unpaid interest, if any, on the Securities repurchased, to, but excluding, the date of purchase (the “Change of Control Payment”).

 

Within 30 days following any Change of Control Triggering Event or, at the Company’s option, prior to any Change of Control but after the public announcement of the pending Change of Control, the Company will be required to deliver a notice to Holders of Securities describing the transaction or transactions that constitute or may constitute the Change of Control Triggering Event and offering to repurchase the Securities on the date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is delivered (the “Change of Control Payment Date”), pursuant to the procedures required herein and described in such notice.  The Company must comply with the requirements of Rule 14e-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the Securities as a result of a Change of Control Triggering Event.  To the extent that the provisions of any securities laws or regulations conflict with the Change of Control provisions herein, the Company will be required to comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under the Change of Control provisions herein by virtue of such conflicts.

 

On the Change of Control Payment Date, the Company will be required, to the extent lawful, to:

 

A-7











 

(a)        accept for payment all Securities or portions of Securities properly tendered, and not validly withdrawn, pursuant to the Change of Control Offer;

 

(b)        deposit with the Paying Agent an amount equal to the Change of Control Payment in respect of all Securities or portions of Securities properly tendered and not validly withdrawn; and

 

(c)        deliver or cause to be delivered to the Trustee the Securities properly accepted together with an Officers’ Certificate stating the aggregate principal amount of Securities or portions of Securities being purchased by the Company.

 

The Paying Agent will be required to deliver promptly to each Holder who properly tendered Securities the purchase price for such Securities and the Trustee will be required to authenticate and deliver (or cause to be transferred by book entry) promptly to each such Holder a new Security equal in principal amount to any unpurchased portion of the Securities surrendered, if any; provided that each new Security will be in a principal amount of $2,000 or in any integral multiples of $1,000 in excess thereof.

 

For purposes of the foregoing discussion of a repurchase at the option of Holders, the following definitions are applicable:

 

“Capital Stock” means the capital stock of every class whether now or hereafter authorized, regardless of whether such capital stock shall be limited to a fixed sum or percentage with respect to the rights of the holders thereof to participate in dividends and in the distribution of assets upon the voluntary or involuntary liquidation, dissolution or winding up of such corporation.

 

“Change of Control” means the occurrence of any of the following:

 

(a)        the direct or indirect sale, lease, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more series of related transactions, of all or substantially all of the Company’s assets and the assets of its Subsidiaries, taken as a whole, to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act), other than the Company or one of its Subsidiaries;

 

(b)        the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) other than the Company or one of its Subsidiaries, becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of more than 50% of the Company’s then outstanding Voting Stock or other Voting Stock into which the Company’s Voting Stock is reclassified, consolidated, exchanged or changed, measured by voting power rather than number of shares;

 

(c)        the first day on which a majority of the Company’s members of its board of directors are not Continuing Directors; or

 

(d)       the adoption of a plan relating to the Company’s liquidation or dissolution.

 

A-8











 

Notwithstanding the foregoing, a transaction will not be considered to be a Change of Control if (a) the Company becomes a direct or indirect wholly-owned subsidiary of a holding company and (b)(x) immediately following that transaction, the direct or indirect holders of the Voting Stock of the holding company are substantially the same as the holders of the Company’s Voting Stock immediately prior to that transaction or (y) immediately following that transaction, no person is the beneficial owner, directly or indirectly, of more than 50% of the Voting Stock of such holding company.

 

“Change of Control Triggering Event” means the occurrence of both a Change of Control and a Rating Event.

 

“Continuing Directors” means, as of any date of determination, any member of the Company’s board of directors who (a) was a member of such board of directors on April 2, 2013 or (b) was nominated for election, elected or appointed to such board of directors with the approval of a majority of the Continuing Directors who were members of such board of directors at the time of such nomination, election or appointment (either by a specific vote or by approval of a proxy statement in which such member was named as a nominee for election as a director).

 

“Fitch” means Fitch, Inc. and its successors.

 

“Investment Grade” means a rating of Baa3 or better by Moody’s (or its equivalent under any successor rating categories of Moody’s), a rating of BBB- or better by S&P (or its equivalent under any successor rating categories of S&P) and a rating of BBB- or better by Fitch (or its equivalent under any successor rating categories of Fitch).

 

“Moody’s” means Moody’s Investors Service, Inc., a subsidiary of Moody’s Corporation, and its successors.

 

“Rating Agencies” means (a) each of Moody’s, S&P and Fitch; and (b) if any of Moody’s, S&P or Fitch ceases to rate the Securities or fails to make a rating of the Securities publicly available for reasons outside of the Company’s control, a “nationally recognized statistical rating organization” within the meaning of Section 3(a)(62) under the Exchange Act that is selected by the Company (as certified by a resolution of the Company’s board of directors) as a replacement agency for Moody’s, S&P or Fitch, or each of them, as the case may be.

 

“Rating Event” means, with respect to the Securities, the rating on the Securities is lowered below Investment Grade by any two of the three Rating Agencies on any date during the period commencing 60 days prior to the public notice of an arrangement that could result in a Change of Control until the end of the 60-day period following public notice of the occurrence of the Change of Control (which 60-day period shall be extended so long as the rating of the Securities is under publicly announced consideration for possible downgrade by any of the Rating Agencies), provided that a Rating Event otherwise arising by virtue of a particular reduction in, or termination of, any rating shall not be deemed to have occurred with respect to a particular Change of Control (and thus shall not be deemed a Rating Event for purposes of the definition of Change of Control Triggering Event hereunder) if the Rating Agency or Rating Agencies ceasing to rate the Securities or making the reduction in rating to which this definition

 

A-9











 

would otherwise apply do not announce or publicly confirm or inform the Trustee in writing at its request that the termination or reduction was the result, in whole or in part, of any event or circumstance comprised of or arising as a result of, or in respect of, the applicable Change of Control (whether or not the applicable Change of Control shall have occurred at the time of the Rating Event).

 

“S&P” means Standard & Poor’s Ratings Services, a division of The McGraw-Hill Companies, Inc., and its successors.

 

“Voting Stock” means, with respect to any specified person as of any date, the Capital Stock of such person that is at the time entitled to vote generally in the election of the board of directors of such person.

 

The Indenture contains provisions for defeasance at any time of the entire indebtedness of this Security or certain restrictive covenants and Events of Default with respect to this Security, in each case upon compliance with certain conditions set forth in the Indenture, which provisions apply to this Security.  This Security is not subject to repayment at the Holder’s option.

 

No reference herein to the Indenture and no provision of this Security or the Indenture shall affect or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of, premium, if any, and interest on this Security at the respective due dates, place and rate, and in the Currency herein prescribed.

 

Default and Remedies.  If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture.

 

Amendment, Modification and Waiver.  The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time outstanding of each series to be affected.  The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities of each series at the time outstanding, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences.

 

Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security.

 

Denominations; Transfer and Exchange.  As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the records of the Registrar, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Registrar duly executed by, the Holder hereof or the

 

A-10











 

Holder’s attorney duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees.

 

The Securities of this series are issuable only in registered form in denominations of $2,000 and any integral multiples of $1,000 in excess thereof.  As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same.

 

No service charge shall be made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith.

 

Persons Deemed Owners.  Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee shall treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary.

 

Miscellaneous.  The Indenture and the Securities, including this Security, shall be governed by and construed in accordance with the law of the State of New York.

 

All terms used in this Security and not defined herein shall have the meanings assigned to them in the Indenture.

 

Pursuant to a recommendation promulgated by the Committee on Uniform Security Identification Procedures, the Company has caused “CUSIP” numbers to be printed on the Securities as a convenience to the Holders of the Securities.  No representation is made as to the correctness or accuracy of such CUSIP numbers as printed on the Securities, and reliance may be placed only on the other identification numbers printed hereon.

 

Unless the certificate of authentication hereon has been executed by or on behalf of the Trustee by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose.

 

A-11











 

ASSIGNMENT FORM

 

 

FOR VALUE RECEIVED, the undersigned hereby
 sells, assigns and transfers unto

 

 

PLEASE INSERT SOCIAL
 SECURITY OR OTHER IDENTIFYING
 NUMBER OF ASSIGNEE

 




 


 



(Please Print or Typewrite Name and Address, including Zip Code, of Assignee)


 

 



the within Security of St. Jude Medical, Inc. and                     hereby does irrevocably constitute and appoint

 


 



Attorney to transfer said Security on the books of the within-named Company with full power of substitution in the premises

 

	
Dated:
    	
 
    
	
 
    
	
Signature
    	
 
    
			


 

NOTICE: The signature to this assignment must correspond with the name as it appears on the first page of the within Security in every particular, without alteration or enlargement or any change whatever.

 

	
Signature
    
	
Guaranteed:
    	
 
    


 

NOTICE: Signature(s) must be guaranteed by an “eligible guarantor institution” that is a member or participant in a “signature guarantee program” (e.g., the Securities Transfer Agents Medallion Program, the Stock Exchange Medallion Program and the New York Stock Exchange Medallion Program).

 

A-12











 

SCHEDULE OF INCREASES OR DECREASES IN GLOBAL SECURITY

 

The following increases or decreases in this Global Security have been made:

 

	
Date of Exchange
    	
 
    	
Amount of increase in
   Principal Amount of
   this Global Security
    	
 
    	
Amount of decrease
   in Principal Amount
   of this Global
   Security
    	
 
    	
Principal Amount of
   this Global Security
   following such
   decrease or increase
    	
 
    	
Signature of
   authorized signatory
   of Trustee
    	
 
    


 

A-13